Figure 3.

Subgroup analyses of PFS and OS in Nivolumab treated NSCLC patients with different NLR. A, low baseline NLR versus high baseline NLR for PFS combined from different cutoff value; B, low baseline NLR versus high baseline NLR for OS combined from different cutoff value; C, low NLR versus high NLR for PFS, subsets were baseline NLR and post-treatment NLR; D, low NLR versus high NLR for OS, subsets were baseline NLR and post-treatment NLR. Baseline NLR was defined as NLR before Nivolumab treatment, post-treatment NLR was defined as NLR after Nivolumab treatment.